[The influence of the new beta sympathicolytic agent carazolol on sympathicotonic false regulation (author's transl)].
In 18 patients with tachycardia at rest the effect of treatment with the beta sympathicolytic agent Carazolol was investigated, using Schellong's test, venous occlusion plethysmography, ECG and a questionaire evaluating concomitant effects. A significant reduction in heart rate (about 20 percent) as well as a decrease in systolic blood pressure were observed. No further therapeutical effect was seen during long term treatment. There wer no significant influences on venous occlusion plethysmography and ECG. The patients reported a considerable improvement of their heart complaints.
D000293:Adolescent; D000328:Adult; D001794:Blood Pressure; D002227:Carbazoles / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000188:drug therapy*; D004562:Electrocardiography; D006801:Humans; D008297:Male; D008875:Middle Aged; D010991:Plethysmography; D011412:Propanolamines / Q000627:therapeutic use*; D011674:Pulse; D013564:Sympathetic Nervous System; D013610:Tachycardia / Q000175:diagnosis / Q000188:drug therapy
D002227:Carbazoles; D011412:Propanolamines; C014382:carazolol
Die Wirkung des neuen Betarezeptorenblockers Carazolol bei sympathikotoner Fehlregulation des Kreislaufs.